Camilla Foged

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8527780/publications.pdf

Version: 2024-02-01

112 papers	6,173 citations	66343 42 h-index	76900 74 g-index
118 all docs	118 docs citations	118 times ranked	8121 citing authors

#	Article	IF	Citations
1	Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. International Journal of Pharmaceutics, 2022, 621, 121758.	5.2	26
2	Engineering of Solid Dosage Forms of siRNA-Loaded Lipidoidâ€“Polymer Hybrid Nanoparticles Using a Quality-by-Design Approach. Methods in Molecular Biology, 2021, 2282, 137-157.	0.9	2
3	Delivery of oligonucleotideâ€based therapeutics: challenges and opportunities. EMBO Molecular Medicine, 2021, 13, e13243.	6.9	181
4	Adsorption of protein antigen to the cationic liposome adjuvant CAFÂ®01 is required for induction of Th1 and Th17 responses but not for antibody induction. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 293-305.	4.3	9
5	Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects. Pharmaceutics, 2021, 13, 177.	4.5	18
6	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in Immunology, 2020, 11, 1817.	4.8	189
7	Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-Î± siRNA with PAMAM dendrimers in a murine model. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 114-120.	4.3	49
8	Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone. Frontiers in Immunology, 2020, 11, 803.	4.8	15
9	Nanoparticles for mucosal vaccine delivery. , 2020, , 603-646.		24
10	Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics, 2020, 12, 102.	4.5	320
11	Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-Î± siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles. Frontiers in Bioengineering and Biotechnology, 2020, 8, 601155.	4.1	11
12	Identification of Factors of Importance for Spray Drying of Small Interfering RNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles for Inhalation. Pharmaceutical Research, 2019, 36, 142.	3.5	39
13	Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. Journal of Controlled Release, 2019, 310, 82-93.	9.9	33
14	Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles. Molecular Pharmaceutics, 2019, 16, 4725-4737.	4.6	5
15	Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 38-48.	4.3	46
16	Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 140, 29-39.	4.3	19
17	Nebulised lipidâ€“polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells. ERJ Open Research, 2019, 5, 00161-2018.	2.6	35
18	Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. AAPS PharmSciTech, 2019, 20, 137.	3.3	16

#	Article	IF	Citations
19	Qualitative and quantitative analysis of the biophysical interaction of inhaled nanoparticles with pulmonary surfactant by using quartz crystal microbalance with dissipation monitoring. Journal of Colloid and Interface Science, 2019, 545, 162-171.	9.4	21
20	Preparation, Characterization, and In Vitro Evaluation of Lipidoidâ€“Polymer Hybrid Nanoparticles for siRNA Delivery to the Cytosol. Methods in Molecular Biology, 2019, 1943, 141-152.	0.9	18
21	Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery. Pharmaceutical Research, 2019, 36, 37.	3.5	11
22	Macrophage Phosphoproteome Analysis Reveals MINCLE-dependent and -independent Mycobacterial Cord Factor Signaling. Molecular and Cellular Proteomics, 2019, 18, 669-685.	3.8	20
23	Microfluidics-based self-assembly of peptide-loaded microgels: Effect of three dimensional (3D) printed micromixer design. Journal of Colloid and Interface Science, 2019, 538, 559-568.	9.4	19
24	Immune Reactions in the Delivery of RNA Interference-Based Therapeutics: Mechanisms and Opportunities. , 2019, , 441-472.		0
25	Lipid Shell-Enveloped Polymeric Nanoparticles with High Integrity of Lipid Shells Improve Mucus Penetration and Interaction with Cystic Fibrosis-Related Bacterial Biofilms. ACS Applied Materials & Interfaces, 2018, 10, 10678-10687.	8.0	21
26	Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Proteinâ€“Based Fusion Antigen CTH522 Into Protein Nanoparticles. Journal of Pharmaceutical Sciences, 2018, 107, 1690-1700.	3.3	3
27	Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder. Vaccine, 2018, 36, 3331-3339.	3.8	33
28	Engineering of budesonide-loaded lipid-polymer hybrid nanoparticles using a quality-by-design approach. International Journal of Pharmaceutics, 2018, 548, 740-746.	5.2	31
29	A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522. Journal of Controlled Release, 2018, 271, 88-97.	9.9	48
30	Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities. Therapeutic Delivery, 2018, 9, 731-749.	2.2	18
31	Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying. Pharmaceutical Research, 2018, 35, 247.	3.5	21
32	Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization. Frontiers in Immunology, 2018, 9, 2825.	4.8	23
33	Insight into Nanoscale Network of Spray-Dried Polymeric Particles: Role of Polymer Molecular Conformation. ACS Applied Materials & Interfaces, 2018, 10, 36686-36692.	8.0	8
34	Temperature-Induced Self-Assembly of the Group B Streptococcus (GBS) Fusion Antigen GBS-NN. Molecular Pharmaceutics, 2018, 15, 2584-2593.	4.6	5
35	Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein. Journal of Controlled Release, 2018, 285, 12-22.	9.9	17
36	Immunogenicity Testing of Lipidoids InÂVitro and In Silico: Modulating Lipidoid-Mediated TLR4 Activation by Nanoparticle Design. Molecular Therapy - Nucleic Acids, 2018, 11, 159-169.	5.1	27

#	Article	IF	Citations
37	Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). Frontiers in Immunology, 2018, 9, 898.	4.8	18
38	Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA. Molecular Pharmaceutics, 2017, 14, 2294-2306.	4.6	11
39	Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. Journal of Controlled Release, 2017, 260, 78-91.	9.9	50
40	Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses. Pharmaceutical Research, 2017, 34, 1716-1727.	3.5	8
41	Anti-Inflammatory Effect of Anti-TNF-Î± SiRNA Cationic Phosphorus Dendrimer Nanocomplexes Administered Intranasally in a Murine Acute Lung Injury Model. Biomacromolecules, 2017, 18, 2379-2388.	5.4	78
42	Engineering of small interfering RNA-loaded lipidoid-poly(DL -lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 120, 22-33.	4.3	53
43	Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 120, 9-21.	4.3	40
44	Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics, 2016, 8, 7.	4.5	147
45	Nano-Self-Assemblies Based on Synthetic Analogues of Mycobacterial Monomycoloyl Glycerol and DDA: Supramolecular Structure and Adjuvant Efficacy. Molecular Pharmaceutics, 2016, 13, 2771-2781.	4.6	12
46	The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8 + T-cell responses: The immunological consequences of the biodistribution profile. Journal of Controlled Release, 2016, 239, 107-117.	9.9	62
47	Conserved Molecular Superlattices in a Series of Homologous Synthetic Mycobacterial Cell-Wall Lipids Forming Interdigitated Bilayers. Langmuir, 2016, 32, 12693-12701.	3.5	4
48	Trehalose diester glycolipids are superior to the monoesters in binding to Mincle, activation of macrophages inÂvitro and adjuvant activity inÂvivo. Innate Immunity, 2016, 22, 405-418.	2.4	47
49	Delivery of siRNA Complexed with Palmitoylated Î±-Peptide/Î²-Peptoid Cell-Penetrating Peptidomimetics: Membrane Interaction and Structural Characterization of a Lipid-Based Nanocarrier System. Molecular Pharmaceutics, 2016, 13, 1739-1749.	4.6	19
50	Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We?. Current Pharmaceutical Design, 2016, 22, 2561-2576.	1.9	16
51	Influence of trehalose 6,6â€²-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 80-89.	4.3	19
52	Surface coating of siRNAâ€“peptidomimetic nano-self-assemblies with anionic lipid bilayers: enhanced gene silencing and reduced adverse effects in vitro. Nanoscale, 2015, 7, 19687-19698.	5.6	16
53	Mechanistic profiling of the siRNA delivery dynamics of lipidâ€“polymer hybrid nanoparticles. Journal of Controlled Release, 2015, 201, 22-31.	9.9	66
54	Classification of Vaccines. Advances in Delivery Science and Technology, 2015, , 15-29.	0.4	18

#	Article	IF	Citations
55	Nanoparticle-mediated delivery of the antimicrobial peptide plectasin against Staphylococcus aureus in infected epithelial cells. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 92, 65-73.	4.3	56
56	Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosanâ€“poly(ethylene imine) hybrid nanoparticles: A mechanistic insight. Journal of Controlled Release, 2015, 211, 1-9.	9.9	48
57	Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. Journal of Controlled Release, 2015, 210, 48-57.	9.9	76
58	Hyaluronic Acid-Based Nanogels Produced by Microfluidics-Facilitated Self-Assembly Improves the Safety Profile of the Cationic Host Defense Peptide Novicidin. Pharmaceutical Research, 2015, 32, 2727-35.	3.5	32
59	Improved insulin loading in poly(lactic-co-glycolic) acid (PLGA) nanoparticles upon self-assembly with lipids. International Journal of Pharmaceutics, 2015, 482, 84-91.	5.2	40
60	Characterizing the Association Between Antigens and Adjuvants. Advances in Delivery Science and Technology, 2015, , 413-426.	0.4	2
61	A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⁺ T-cell response. Nanomedicine, 2014, 9, 2625-2638.	3.3	13
62	Mechanism of Action of Lung Damage Caused by a Nanofilm Spray Product. Toxicological Sciences, 2014, 140, 436-444.	3.1	16
63	The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 480-488.	4.3	20
64	One-Step Production of Protein-Loaded PLGA Microparticles via Spray Drying Using 3-Fluid Nozzle. Pharmaceutical Research, 2014, 31, 1967-1977.	3.5	41
65	Modulating Protein Release Profiles by Incorporating Hyaluronic Acid into PLGA Microparticles Via a Spray Dryer Equipped with a 3-Fluid Nozzle. Pharmaceutical Research, 2014, 31, 2940-2951.	3.5	24
66	Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge. Expert Opinion on Drug Delivery, 2014, 11, 1481-1495.	5.0	22
67	Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: Effect of charge, fluidity and antigen-to-lipid ratio. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2001-2010.	2.6	35
68	The Physical Stability of the Recombinant Tuberculosis Fusion Antigens H1 and H56. Journal of Pharmaceutical Sciences, 2013, 102, 3567-3578.	3.3	21
69	Evaluation of carrier-mediated siRNA delivery: Lessons for the design of a stem-loop qPCR-based approach for quantification of intracellular full-length siRNA. Journal of Controlled Release, 2013, 166, 220-226.	9.9	9
70	Impact of PLGA molecular behavior in the feed solution on the drug release kinetics of spray dried microparticles. Polymer, 2013, 54, 5920-5927.	3.8	24
71	Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01. Journal of Controlled Release, 2013, 167, 256-264.	9.9	38
72	Protein Antigen Adsorption to the DDA/TDB Liposomal Adjuvant: Effect on Protein Structure, Stability, and Liposome Physicochemical Characteristics. Pharmaceutical Research, 2013, 30, 140-155.	3.5	43

#	Article	IF	Citations
73	Critical Solvent Properties Affecting the Particle Formation Process and Characteristics of Celecoxib-Loaded PLGA Microparticles via Spray-Drying. Pharmaceutical Research, 2013, 30, 1065-1076.	3.5	59
74	Engineering of an Inhalable DDA/TDB Liposomal Adjuvant: A Quality-by-Design Approach Towards Optimization of the Spray Drying Process. Pharmaceutical Research, 2013, 30, 2772-2784.	3.5	44
75	The supramolecular structure is decisive for the immunostimulatory properties of synthetic analogues of a mycobacterial lipid in vitro. RSC Advances, 2013, 3, 20673-20683.	3.6	16
76	Lipid-based colloidal carriers for targeted siRNA delivery. Therapeutic Delivery, 2012, 3, 1245-1247.	2.2	0
77	siRNA Delivery with Lipid-based Systems: Promises and Pitfalls. Current Topics in Medicinal Chemistry, 2012, 12, 97-107.	2.1	51
78	Interaction of Peptidomimetics with Bilayer Membranes: Biophysical Characterization and Cellular Uptake. Langmuir, 2012, 28, 5167-5175.	3.5	28
79	Calcipotriol delivery into the skin with PEGylated liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 532-539.	4.3	80
80	Membrane adsorption and binding, cellular uptake and cytotoxicity of cell-penetrating peptidomimetics with Î±-peptide/Î²-peptoid backbone: Effects of hydrogen bonding and Î±-chirality in the Î²-peptoid residues. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2660-2668.	2.6	20
81	Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin Î±2Î²1 receptor. International Journal of Pharmaceutics, 2012, 428, 171-177.	5.2	16
82	License to kill: Formulation requirements for optimal priming of CD8+ CTL responses with particulate vaccine delivery systems. European Journal of Pharmaceutical Sciences, 2012, 45, 482-491.	4.0	103
83	Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. Journal of Controlled Release, 2012, 157, 141-148.	9.9	162
84	MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. Journal of Controlled Release, 2012, 161, 772-780.	9.9	55
85	Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression. Pharmaceutical Research, 2012, 29, 669-682.	3.5	36
86	Stabilization of liposomes during drying. Expert Opinion on Drug Delivery, 2011, 8, 375-388.	5.0	114
87	Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Therapeutic Delivery, 2011, 2, 1057-1077.	2.2	116
88	Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 89-98.	4.3	47
89	High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 26-35.	4.3	191
90	Immunity by formulation design: Induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. Journal of Controlled Release, 2011, 150, 307-317.	9.9	85

#	Article	IF	Citations
91	Targeting of liposome-associated calcipotriol to the skin: Effect of liposomal membrane fluidity and skin barrier integrity. International Journal of Pharmaceutics, 2011, 416, 478-485.	5.2	40
92	Elucidating the molecular mechanism of PAMAMâ€“siRNA dendriplex self-assembly: Effect of dendrimer charge density. International Journal of Pharmaceutics, 2011, 416, 410-418.	5.2	77
93	Incorporation of the TLR4 Agonist Monophosphoryl Lipid A Into the Bilayer of DDA/TDB Liposomes: Physico-Chemical Characterization and Induction of CD8+ T-Cell Responses In Vivo. Pharmaceutical Research, 2011, 28, 553-562.	3.5	51
94	CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. International Journal of Pharmaceutics, 2010, 390, 19-24.	5.2	54
95	Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. Journal of Controlled Release, 2010, 142, 138-145.	9.9	176
96	Preparation and characterization of poly(dl-lactide-co-glycolide) nanoparticles for siRNA delivery. International Journal of Pharmaceutics, 2010, 390, 70-75.	5.2	98
97	Molecular Characterization of the Interaction between siRNA and PAMAM G7 Dendrimers by SAXS, ITC, and Molecular Dynamics Simulations. Biomacromolecules, 2010, 11, 3571-3577.	5.4	75
98	Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opinion on Drug Delivery, 2009, 6, 657-672.	5.0	81
99	Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opinion on Drug Delivery, 2008, 5, 105-117.	5.0	177
100	NIR transmission spectroscopy for rapid determination of lipid and lyoprotector content in liposomal vaccine adjuvant system CAF01. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 914-920.	4.3	19
101	Î±,Î±â€²-trehalose 6,6â€²-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 1365-1373.	2.6	36
102	Cellular uptake and membrane-destabilising properties of Î±-peptide/Î²-peptoid chimeras: lessons for the design of new cell-penetrating peptides. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 2487-2495.	2.6	55
103	Polymeric Nanocarriers for siRNA Delivery: Challenges and Future Prospects. Journal of Biomedical Nanotechnology, 2008, 4, 258-275.	1.1	27
104	Phospholipase A₂Sensitive Liposomes for Delivery of Small Interfering RNA (siRNA). Journal of Liposome Research, 2007, 17, 191-196.	3.3	20
105	Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 2120-2129.	2.6	79
106	Antiplasmodial and Prehemolytic Activities of Î±â€Peptideâ€“Î²â€Peptoid Chimeras. ChemBioChem, 2007, 8, 1781-1784.	2.6	41
107	Liposomes for phospholipase A2 triggered siRNA release: Preparation and in vitro test. International Journal of Pharmaceutics, 2007, 331, 160-166.	5.2	58
108	The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology, 2007, 121, 216-226.	4.4	167

#	Article	IF	Citations
109	Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. International Journal of Pharmaceutics, 2005, 298, 315-322.	5.2	741
110	Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine, 2004, 22, 1903-1913.	3.8	181
111	Inhalable Composite Microparticles Containing siRNA-Loaded Lipid-Polymer Hybrid Nanoparticles: Saccharides and Leucine Preserve Aerosol Performance and Long-Term Physical Stability. Frontiers in Drug Delivery, 0, 2, .	1.6	3
112	Grand Challenges in Vaccine Delivery: Lessons Learned From the COVID-19 Vaccine Rollout. Frontiers in Drug Delivery, 0, 2, .	1.6	1